AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Axin-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O15169

UPID:

AXIN1_HUMAN

Alternative names:

Axis inhibition protein 1

Alternative UPACC:

O15169; Q4TT26; Q4TT27; Q86YA7; Q8WVW6; Q96S28

Background:

Axin-1, also known as Axis inhibition protein 1, plays a crucial role in the beta-catenin destruction complex, pivotal for Wnt-signaling modulation and cell development. It regulates CTNNB1 levels through phosphorylation and ubiquitination, influencing both cell growth and apoptosis. Axin-1's involvement in dorsoventral patterning and its function as a component of the AXIN1-HIPK2-TP53 complex underline its significance in cellular processes.

Therapeutic significance:

Axin-1's association with Hepatocellular carcinoma and Caudal duplication anomaly highlights its potential as a therapeutic target. Its role in disease pathogenesis, particularly through the hypermethylation of the AXIN1 promoter in Caudal duplication anomaly, underscores the importance of understanding Axin-1 in developing treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.